Lantern Pharma receives Taiwan approvals to open next stage of Phase 2 HARMONIC trial
LTRN•Lantern Pharma received Taiwan approvals to open the next stage of its Phase 2 HARMONIC trial of LP-300 in never-smokers with EGFR-mutant NSCLC. The company plans to open additional Taiwan sites for Part 2 enrollment.
1. Taiwan trial approvals
Lantern Pharma received Taiwan approvals to open the next stage of its Phase 2 HARMONIC trial of LP-300 in never-smokers with EGFR-mutant NSCLC. It plans to open additional sites in Taiwan for Part 2 enrollment.
